Dynavax Technologies (NASDAQ:DVAX – Get Rating) released its earnings results on Thursday. The biopharmaceutical company reported $0.22 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.02), MarketWatch Earnings reports. Dynavax Technologies had a return on equity of 115.98% and a net margin of 23.12%. During the same quarter in the previous year, the company posted $0.01 earnings per share.
DVAX stock traded up $0.18 during trading on Friday, hitting $8.94. 3,382,106 shares of the company’s stock traded hands, compared to its average volume of 1,417,119. The firm has a market capitalization of $1.13 billion, a P/E ratio of 16.25 and a beta of 1.44. Dynavax Technologies has a 1 year low of $7.09 and a 1 year high of $21.39. The company has a quick ratio of 1.64, a current ratio of 1.75 and a debt-to-equity ratio of 0.99. The business has a fifty day simple moving average of $10.48 and a two-hundred day simple moving average of $13.21.
In other Dynavax Technologies news, SVP Robert Janssen sold 24,036 shares of the stock in a transaction dated Thursday, March 3rd. The stock was sold at an average price of $10.57, for a total value of $254,060.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO David F. Novack sold 41,862 shares of the company’s stock in a transaction that occurred on Thursday, March 3rd. The shares were sold at an average price of $10.57, for a total transaction of $442,481.34. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 170,496 shares of company stock valued at $1,801,527. 9.31% of the stock is owned by company insiders.
Several research firms have recently commented on DVAX. StockNews.com began coverage on shares of Dynavax Technologies in a report on Thursday, March 31st. They issued a “buy” rating on the stock. Zacks Investment Research downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Tuesday, March 1st. HC Wainwright assumed coverage on shares of Dynavax Technologies in a research note on Wednesday, January 12th. They set a “buy” rating and a $28.00 price target on the stock. Finally, TheStreet raised shares of Dynavax Technologies from a “d+” rating to a “c” rating in a research note on Wednesday, March 30th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $21.00.
About Dynavax Technologies (Get Rating)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
- Get a free copy of the StockNews.com research report on Dynavax Technologies (DVAX)
- Nasdaq Stock is a Buy the (Deep) Dip Opportunity
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.